Identification of an Alternative Glycyrrhizin Metabolite Causing Liquorice-Induced Pseudohyperaldosteronism and the Development of ELISA System to Detect the Predictive Biomarker
- 1Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
- 2Department of Natural Medicines, Daiichi University of Pharmacy, Fukuoka, Japan
- 3Center for Kampo Medicine, Keio University School of Medicine, Tokyo, Japan
- 4Department of Otorhinolaryngology and Head and Neck Surgery, Clinic of Japanese Oriental (Kampo) Medicine, Kanazawa University Hospital, Kanazawa, Japan
- 5Department of Oriental Medicine, Kameda Medical Center, Kamogawa, Japan
- 6Department of Japanese Oriental (Kampo) Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
glycyrrhizin metabolite causing liquorice-induced pseudohyperaldosteronism and the development of ELISA system to detect the predictive biomarker by Ishiuchi K, Morinaga O, Yoshino T, Mitamura M, Hirasawa A, Maki Y, Tashita Y, Kondo T, Ogawa K, Lian F, Ogawa-Ochiai K, Minamizawa K, Namiki T, Mimura M, Watanabe K and Makino T (2021). Front. Pharmacol. 12:688508. doi: 10.3389/fphar.2021.688508
In the published article, there was an error. The numbers of the concentrations were mistaken.
A correction has been made to Results, Pharmacokinetics of GA metabolites in female and male EHBRs orally treated with GA, Paragraph 7. These sentences previously stated:
“The concentrations of GA and its metabolites 12 h after oral administration of GA in female EHBRs were 3.2 µM of GA, 0.1 µM of 3MGA, 14 µM of 1, 4.3 µM of 2, 6.6 µM of 3, and 166 µM of 4.”
and
“The concentrations of GA and its metabolites 12 h after oral administration of GA in male EHBRs were 2.6 µM of GA, 1.2 µM of 3MGA, 102 µM of 1, 4.1 µM of 2, 1.2 µM of 3, and 198 µM of 4.”
The corrected sentences appear below:
“The concentrations of GA and its metabolites 12 h after oral administration of GA in female EHBRs were 2.7 µM of GA, 0.1 µM of 3MGA, 32 µM of 1, 10 µM of 2, 2.0 µM of 3, and 208 µM of 4.”
and
“The concentrations of GA and its metabolites 12 h after oral administration of GA in male EHBRs were 2.6 µM of GA, 1.6 µM of 3MGA, 177 µM of 1, 8.2 µM of 2, 2.2 µM of 3, and 237 µM of 4.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: kampo medicine, side effect, liquorice, glycyrrhizin, pseudoaldosteronism, sex differences
Citation: Ishiuchi K, Morinaga O, Yoshino T, Mitamura M, Hirasawa A, Maki Y, Tashita Y, Kondo T, Ogawa K, Lian F, Ogawa-Ochiai K, Minamizawa K, Namiki T, Mimura M, Watanabe K and Makino T (2022) Corrigendum: Identification of an alternative glycyrrhizin metabolite causing liquorice-induced pseudohyperaldosteronism and the development of ELISA system to detect the predictive biomarker. Front. Pharmacol. 13:1090327. doi: 10.3389/fphar.2022.1090327
Received: 05 November 2022; Accepted: 10 November 2022;
Published: 24 November 2022.
Edited and reviewed by:
Wei Li, Toho University, JapanCopyright © 2022 Ishiuchi, Morinaga, Yoshino, Mitamura, Hirasawa, Maki, Tashita, Kondo, Ogawa, Lian, Ogawa-Ochiai, Minamizawa, Namiki, Mimura, Watanabe and Makino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Toshiaki Makino, makino@phar.nagoya-cu.ac.jp
†These authors have contributed equally to this work
‡Present address: Kampo Clinical Center, Department of General Medicine, Hiroshima University Hospital, Hiroshima, Japan